CompletedNCT05876221
Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
Studying Immune-mediated thrombotic thrombocytopenic purpura
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Cologne
- Principal Investigator
- Lucas Kühne, MDDepartment II of Internal Medicine, University Hospital of Cologne
- Intervention
- Cablivi(drug)
- Enrollment
- 223 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- University Hospital of Cologne, Cologne, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05876221 on ClinicalTrials.govOther trials for Immune-mediated thrombotic thrombocytopenic purpura
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06831058A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)University of Minnesota
- ACTIVE NOT RECRUITINGNCT05046717Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic PurpuraFundación Española de Hematología y Hemoterapía
- ACTIVE NOT RECRUITINGNCT04985318Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTPUniversity of Cologne
See all trials for Immune-mediated thrombotic thrombocytopenic purpura →